SARS-CoV-2 disrupts the human immune system at nearly every level, from silencing the body’s earliest antiviral alarms to reprogramming immune cells long after the virus is cleared. Over half of the virus’s known proteins have been found to interfere with some part of the immune response, and the downstream consequences range from runaway inflammation and blood clots during acute infection to autoimmune phenomena and chronic symptoms that persist for months or years. Understanding how this dysregulation unfolds helps explain why COVID-19 can look so different from one person to the next, and why the effects sometimes linger well beyond the initial illness.
How the Virus Disarms Early Defenses
The immune system’s first line of defense against any virus is the interferon system, a set of signaling molecules that warn neighboring cells to ramp up antiviral defenses. SARS-CoV-2 is unusually good at shutting this system down. Of the 28 proteins the virus encodes, at least 16 have been shown to impair interferon production or signaling at different stages, from the initial detection of viral material inside a cell all the way through to the expression of antiviral genes.1PubMed Central. Mechanisms of impairment of interferon production by SARS-CoV-2
Several viral proteins work through distinct mechanisms to achieve this suppression. NSP6 and NSP13, for example, both target a key enzyme called TBK1 but block it in different ways: NSP6 binds TBK1 to prevent it from activating a downstream signaling molecule, while NSP13 reduces the levels of activated TBK1 and its target directly. Meanwhile, ORF6 blocks the physical transport of activated signaling molecules into the cell nucleus, where they would otherwise switch on interferon genes.2PubMed Central. Evasion of Type I Interferon by SARS-CoV-2 NSP1 takes a broader approach, suppressing the cell’s ability to translate messenger RNA into protein, which effectively muzzles the production of many host defense molecules at once.3PLOS ONE. SARS-CoV-2 viral proteins NSP1 and NSP13 inhibit interferon activation through distinct mechanisms
What makes this particularly concerning is that SARS-CoV-2 appears to suppress interferon signaling more efficiently than its close relatives SARS-CoV and MERS-CoV, particularly through its versions of NSP1 and NSP6.2PubMed Central. Evasion of Type I Interferon by SARS-CoV-2 This delay in the interferon response buys the virus time to replicate and spread before the immune system fully mobilizes, which in turn sets the stage for the exaggerated inflammatory response that follows in severe cases.
T Cell Depletion and Exhaustion
While the virus is busy suppressing innate defenses, it also takes a toll on the adaptive immune system’s foot soldiers: T cells. Patients with COVID-19, especially those in intensive care, show dramatically reduced numbers of total T cells, CD4+ helper T cells, and CD8+ killer T cells.4PubMed Central. Reduction and Functional Exhaustion of T Cells in Patients With Coronavirus Disease 2019 (COVID-19) This lymphopenia, or shortage of lymphocytes, is one of the most consistent laboratory findings in severe COVID-19 and tracks closely with disease severity.
The T cells that remain are not functioning normally. Studies tracking patients over the course of their illness have found that both CD4+ and CD8+ T cells increasingly express surface markers associated with exhaustion, including PD-1, Tim-3, and NKG2A. These markers ramped up as patients moved from the early prodromal phase into full-blown symptomatic disease and declined again during recovery.5PubMed Central. Peripheral T cell lymphopenia in COVID-19: potential mechanisms and impact In practical terms, this means the T cells that should be killing infected cells and coordinating the broader immune response are instead becoming progressively disabled at the very moment they are needed most.4PubMed Central. Reduction and Functional Exhaustion of T Cells in Patients With Coronavirus Disease 2019 (COVID-19)
When Inflammation Overshoots
The paradox of severe COVID-19 is that the immune system simultaneously does too little and too much. With interferon responses delayed and T cells depleted, the virus replicates unchecked early on. By the time the immune system catches up, it often overcorrects with an outsized inflammatory response sometimes described as a cytokine storm. Circulating monocytes and tissue-resident macrophages are central players in this process, contributing to the inflammatory cascade at every stage, from initial infection through to the organ damage seen in severe disease.6PubMed Central. Monocyte activation in systemic Covid-19 infection: Assay and rationale
This hyperinflammation is not a quirk of the virus alone. It reflects a fundamental mismatch in timing: the suppressed early response allows viral load to climb, and the delayed but explosive immune activation then inflicts collateral damage on the body’s own tissues. The lungs bear the brunt, but the heart, kidneys, blood vessels, and brain can all suffer as a result.
Blood Clots and Vascular Damage
One of the most distinctive features of severe COVID-19 is its tendency to cause widespread clotting. This is not a typical feature of respiratory viruses, and much of the blame falls on an immune mechanism called neutrophil extracellular traps, or NETs. Normally, NETs are webs of DNA and proteins that neutrophils release to snare bacteria. In COVID-19, they are produced in excess and become potent triggers for both inflammation and clotting.
NETs activate clotting pathways through multiple routes: they stimulate the contact pathway of coagulation through electrostatic interactions, present tissue factor to kickstart another clotting cascade, and their embedded enzymes degrade natural anticoagulants that normally keep clotting in check.7The Journal of Clinical Investigation. Neutrophil extracellular traps in COVID-19 Research on COVID-19 patients has shown that NET release correlates directly with clotting activity in the body, and that these NETs carry tissue factor, making them functionally procoagulant.8JCI Insight. Complement and tissue factor–enriched neutrophil extracellular traps are key drivers in COVID-19 immunothrombosis
The virus also injures blood vessel linings directly. SARS-CoV-2 enters cells through ACE2, a receptor expressed on endothelial cells throughout the body. When these cells are damaged, they become activated, more permeable, and more prone to promoting inflammation and clot formation. This endothelial injury helps explain why COVID-19 can cause problems in almost any organ, from the lungs and heart to the kidneys and brain.9PubMed Central. Viral Endothelial Dysfunction: A Unifying Mechanism for COVID-19
Autoantibodies and Molecular Mimicry
Severe COVID-19 sometimes triggers the immune system to attack the body’s own molecules. Among the most striking findings is the discovery that roughly one in ten critically ill COVID-19 patients carry autoantibodies that neutralize type I interferons, the very molecules the body needs to fight off the virus. In one study of nearly a thousand patients with life-threatening COVID-19 pneumonia, at least 101 had these autoantibodies at the onset of critical illness.10PubMed. Autoantibodies against type I IFNs in patients with life-threatening COVID-19 A separate study of ICU patients in Switzerland found a similar rate, with about 11% carrying neutralizing anti-interferon antibodies.11PubMed Central. Critically ill COVID-19 patients with neutralizing autoantibodies against type I interferons have increased risk of herpesvirus disease These antibodies do not just mark severity; they actively block interferons from doing their job, worsening the very immune suppression the virus already causes.
Beyond anti-interferon antibodies, there is growing evidence that SARS-CoV-2 proteins share structural similarities with human proteins, a phenomenon called molecular mimicry. Both computational analyses and laboratory experiments have found that the degree of overlap between viral and human protein sequences is far greater than what would occur by chance.12PubMed Central. Evidence for Molecular Mimicry between SARS-CoV-2 and Human Antigens: Implications for Autoimmunity in COVID-19 When the immune system produces antibodies against these shared sequences, those antibodies can cross-react with the body’s own tissues. Many of the human proteins identified as mimicry targets are involved in processes relevant to COVID-19 pathology or are known targets in established autoimmune diseases.13PubMed. Molecular/antigenic mimicry and immunological cross-reactivity explains SARS-CoV-2-induced autoimmunity This mechanism may help explain the reports of new-onset autoimmune conditions emerging after COVID-19 infection.
Damage to the Brain’s Defenses
The brain is normally protected from circulating immune molecules and pathogens by the blood-brain barrier, a tightly regulated layer of cells lining the brain’s blood vessels. In COVID-19, this barrier breaks down. Autopsy studies of COVID-19 patients found widespread leakage of blood proteins, particularly fibrinogen and immunoglobulins, into brain tissue, a pattern that was absent or minimal in non-COVID controls.14Brain. Neurovascular injury with complement activation and inflammation in COVID-19 This disruption allows inflammatory molecules and immune cells to enter the brain, where they can activate resident immune cells called microglia and damage neurons. The resulting neuroinflammation is thought to contribute to the cognitive symptoms, or “brain fog,” reported by many patients both during and after acute infection.
Why Some People Are Hit Harder
Not everyone who catches COVID-19 experiences severe immune dysregulation, and the differences often come down to preexisting features of the host immune system. Aging is the single biggest risk factor. As people get older, their immune systems undergo a process called immunosenescence: T cells become less diverse, innate immune cells become more prone to chronic low-grade inflammation, and the overall ability to mount a coordinated immune response declines. These age-related changes overlap almost perfectly with the patterns of immune dysfunction seen in severe COVID-19, including exaggerated inflammatory responses and impaired antiviral defenses.15PubMed. Immunosenescence and Inflammaging in COVID-19
Chronic metabolic conditions compound the problem. Research examining patients with obesity, hypertension, and diabetes found that each condition affects different immune cell populations, and when a patient has more than one of these conditions, the immunological disruption adds up. A person with both obesity and diabetes, for instance, has a wider range of immune abnormalities than someone with either condition alone.16PubMed Central. Preexisting comorbidities shape the immune response associated with severe COVID-19 This additive effect helps explain why clusters of metabolic conditions are such strong predictors of severe COVID-19.
Germinal Center Disruption and Weakened Immune Memory
One underappreciated consequence of severe COVID-19 involves the structures where long-term immune memory is built: germinal centers. These are specialized zones in lymph nodes and the spleen where B cells learn to produce highly targeted antibodies through a process of iterative refinement. Autopsy studies of patients who died from COVID-19 revealed a striking absence of germinal centers in both thoracic lymph nodes and spleens, even in patients who survived for weeks after symptom onset.17Cell. Loss of Germinal Centers and T Follicular Helper Cells in Severe COVID-19
Alongside this, there was a dramatic reduction in a specialized type of helper T cell that guides B cells through the germinal center process. Without these cells and structures, the body loses its ability to generate the high-quality, precisely targeted antibodies that provide durable protection. This finding may help explain why some patients who survive severe COVID-19 have weaker or shorter-lived antibody responses compared to those with mild illness. It also underscores a broader point: the virus does not simply evade immunity during acute infection but can structurally damage the machinery that builds lasting immune protection.
Viral Persistence and Its Role in Long COVID
For a subset of patients, immune dysregulation does not resolve when the acute infection ends. A leading explanation for long COVID involves the persistence of viral material, either whole virus or fragments of viral RNA and protein, in tissues throughout the body. Studies using biopsies have detected viral antigen in the small bowel of asymptomatic individuals months after their initial infection. In one study, viral material was found in the gut of half the participants at four months, and those with antigen persistence were more likely to report ongoing symptoms than those without it.18eLife. Viral persistence, reactivation, and mechanisms of long COVID
This persistent viral material appears to act as a continuous stimulus to the immune system. Viral RNA and proteins may engage the body’s pattern-recognition receptors, provoking ongoing cytokine production and inflammation. Over time, this repeated stimulation can exhaust CD4+ and CD8+ T cells, impairing the adaptive immune response in a way that mirrors what happens during acute severe illness but extends for months or years.19PubMed Central. Insights into Persistent SARS-CoV-2 Reservoirs in Chronic Long COVID20Nature Immunology. SARS-CoV-2 reservoir in post-acute sequelae of COVID-19 (PASC)
Mast Cell Activation in Prolonged Illness
Another mechanism gaining attention in long COVID involves mast cells, tissue-resident immune cells found throughout the body, particularly in the skin, gut, and airways. In long COVID patients, mast cells appear to be in a chronically activated state, releasing excessive amounts of inflammatory mediators including histamine and various cytokines.21PubMed Central. Immunological dysfunction and mast cell activation syndrome in long COVID The SARS-CoV-2 spike protein itself can trigger mast cell degranulation through both ACE2 and toll-like receptor 4, and the mediators released by activated mast cells sensitize peripheral nerves, disrupt the blood-brain barrier, and recruit inflammatory cells in the brain. This cascade is thought to contribute to the small-fiber neuropathy, neuroinflammation, and dysautonomia that many long COVID patients experience.22PubMed. Long COVID neuropathy: The role of mast cells
The clinical picture overlaps substantially with mast cell activation syndrome, a condition in which mast cells release their contents inappropriately, causing a range of symptoms from flushing and hives to gastrointestinal distress and brain fog. Recognizing this overlap has practical value: treatments that stabilize mast cells or block the effects of histamine, already used for mast cell activation syndrome, may offer symptomatic relief for some long COVID patients.
Epigenetic Reprogramming of Immune Cells
Perhaps the most unsettling discovery in COVID immunology is that the virus can leave lasting marks on the immune system’s source code. Research published in Cell found that severe COVID-19 causes epigenetic changes, modifications to how genes are read rather than to the genes themselves, in both mature immune cells and in the bone marrow stem cells that produce them. These altered stem cells go on to generate monocytes that are more inflammatory, more prone to migration, and biased toward inflammatory differentiation.23PubMed Central. Epigenetic Memory of Coronavirus Infection in Innate Immune Cells and Their Progenitors
Because monocytes are short-lived cells that are constantly replaced from the bone marrow, epigenetic changes in their progenitor stem cells can perpetuate an inflammatory immune phenotype long after the virus itself is gone. This transmission of epigenetic memory from stem cells to mature monocytes has been proposed as a mechanism for the persistent inflammation seen in long COVID.24PubMed Central. COVID-19 and trained immunity: the inflammatory burden of long covid Intriguingly, researchers found that blocking the inflammatory cytokine IL-6 during acute infection reduced the extent of epigenetic reprogramming in both stem cells and their monocyte offspring, suggesting that the inflammatory surge during the initial illness is what imprints these lasting changes.23PubMed Central. Epigenetic Memory of Coronavirus Infection in Innate Immune Cells and Their Progenitors
Vaccination Versus Infection
One of the clearest illustrations of how dysregulated natural infection can be comes from comparing the immune responses produced by vaccination and by the virus itself. Single-cell analysis of immune cells found that while both inactivated vaccination and natural SARS-CoV-2 infection altered interferon responses, inflammatory cytokine expression, and T cell behavior, the magnitude of change was far greater after infection, especially in severe cases. Severe COVID-19 pushed T cells toward exhaustion and drove down expression of key immune-coordination molecules on B cells, whereas vaccination tended to upregulate those same molecules.25PubMed Central. Single-cell transcriptomic atlas reveals distinct immunological responses between COVID-19 vaccine and natural SARS-CoV-2 infection In other words, vaccination elicited a qualitatively different and more controlled immune response, while the virus itself drove immune cells into dysfunction. This distinction underscores that the immune dysregulation described throughout this article is not simply a byproduct of encountering the spike protein; it is driven by the uncontrolled viral replication, tissue damage, and inflammatory escalation that natural infection produces.
Pediatric Immune Dysregulation and MIS-C
Children generally handle acute COVID-19 well, but a small number develop a delayed inflammatory condition called multisystem inflammatory syndrome in children, or MIS-C, typically two to six weeks after infection. MIS-C involves a dysregulated autoimmune-like response in genetically susceptible children, with a median age of onset between six and eleven years. The condition can affect the heart, gastrointestinal system, skin, and nervous system, and while mortality is low, at roughly one to three percent, the illness is often serious enough to require intensive care.26PubMed Central. Multisystem inflammatory syndrome in children: A dysregulated autoimmune disorder following COVID-19 The timing and clinical features suggest that MIS-C results from an overexaggerated immune response triggered by the virus rather than from the infection itself, echoing the same theme of post-infectious immune dysfunction seen in adults.
Shared Ground With Other Post-Viral Conditions
Long COVID’s resemblance to myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) has not gone unnoticed by researchers. A proteomic study comparing immune cells from long COVID patients and ME/CFS patients found overlapping protein clusters and shared disruptions in molecular pathways, particularly those governing immune function and mitochondrial energy production.27Scientific Reports. A pilot study on the immune cell proteome of long COVID patients shows changes to physiological pathways similar to those in myalgic encephalomyelitis/chronic fatigue syndrome This convergence suggests that post-viral immune dysregulation is not unique to SARS-CoV-2 but represents a broader biological pattern. The massive scale of COVID-19 has, in effect, created the largest-ever cohort of post-viral syndrome patients, providing researchers with an unprecedented opportunity to study mechanisms that may have been operating in other post-infectious conditions for decades. The hope is that what we learn from COVID-19’s immune disruption will eventually shed light on these related illnesses and, ideally, point toward treatments that address the shared underlying biology.